GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,554.50GBp
11:17am EST
Change (% chg)

0.50p (+0.03%)
Prev Close
1,554.00p
Open
1,561.00p
Day's High
1,574.50p
Day's Low
1,553.00p
Volume
5,082,750
Avg. Vol
--
52-wk High
--
52-wk Low
--

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.52
Market Cap(Mil.): £75,173.22
Shares Outstanding(Mil.): 4,864.01
Dividend: 23.00
Yield (%): 5.18

Financials

  GSK.L Industry Sector
P/E (TTM): 27.28 38.99 40.21
EPS (TTM): 0.57 -- --
ROI: 10.43 17.01 16.34
ROE: 48.95 17.53 17.27
Search Stocks

UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia

* GSK's Australian opiates business 2013 revenue was $69.6 mln (Adds Sun Pharma comment, details on Australia poppy industry, share move)

1:04am EST

India's Sun Pharma to buy GSK's opiates business in Australia

MUMBAI, March 3 - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Tuesday it has agreed to buy GlaxoSmithKline's opiates business in Australia.

02 Mar 2015

GSK and Novartis complete deals to reshape both drugmakers

LONDON - GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. | Video

02 Mar 2015

UPDATE 1-GSK and Novartis complete deals to reshape both drugmakers

LONDON, March 2 - GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers.

02 Mar 2015

GSK and Novartis complete deals to reshape both drugmakers

LONDON, March 2 - GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers.

02 Mar 2015

GSK's new chairman Hampton to take charge in May

LONDON - GlaxoSmithKline said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, an earlier transition than initially anticipated.

26 Feb 2015

UPDATE 2-GSK's new chairman Hampton to take charge in May

* GSK facing tough times; CEO's 2014 bonus cut by 51 pct (Adds detail on CEO's reduced bonus, paragraph 5)

26 Feb 2015

GSK's new chairman Hampton to take charge in May

LONDON, Feb 26 - GlaxoSmithKline said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, marking an earlier transition than initially anticipated.

26 Feb 2015

GSK set to complete $20 billion Novartis asset swap next week

LONDON - GlaxoSmithKline said on Wednesday it expected to conclude a $20 billion-plus three-part asset swap with Novartis in the week commencing March 2, following progress in obtaining clearances for the deal.

25 Feb 2015

GSK set to complete $20 bln Novartis asset swap next week

LONDON, Feb 25 - GlaxoSmithKline said on Wednesday it expected to conclude a $20 billion-plus three-part asset swap with Novartis in the week commencing March 2, following progress in obtaining clearances for the deal.

25 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks